Genocea Biosciences, Inc. (GNCA) financial statements (2020 and earlier)

Company profile

Business Address 100 ACORN PARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments402612639447
Cash and cash equivalents402612271720
Short-term investments   367727
Receivables     0
Prepaid expense     0
Deferred costs 0100 
Other current assets     0
Other undisclosed current assets110111
Total current assets:422713649548
Noncurrent Assets
Finance lease, right-of-use asset0
Operating lease, right-of-use asset6
Property, plant and equipment333542
Long-term investments and receivables    12 
Long-term investments    12 
Restricted cash and investments100000
Other noncurrent assets111000
Total noncurrent assets:11446172
TOTAL ASSETS:5331177011250
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities345534
Accounts payable124323
Accrued liabilities     0
Employee-related liabilities222221
Debt1573  
Restructuring reserve  0   
Deferred revenue and credits  01
Other undisclosed current liabilities224221
Total current liabilities:611161066
Noncurrent Liabilities
Long-term debt and lease obligation19108141611
Long-term debt, excluding current maturities13108141611
Finance lease, liability0
Operating lease, liability5
Liabilities, other than long-term debt 00001
Deferred revenue and credits   1
Other liabilities 00000
Other undisclosed noncurrent liabilities23    
Total noncurrent liabilities:21138141712
Total liabilities:282424242218
Stockholders' equity
Stockholders' equity attributable to parent, including:257(6)469033
Common stock000000
Additional paid in capital355299258253248148
Accumulated other comprehensive loss    (0)(0)
Accumulated deficit(331)(292)(264)(207)(158)(115)
Other undisclosed stockholders' equity attributable to parent11    
Total stockholders' equity:257(6)469033
TOTAL LIABILITIES AND EQUITY:5331177011250

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:   010
Operating expenses(39)(40)(55)(48)(42)(33)
Operating loss:(39)(40)(55)(48)(41)(33)
Nonoperating income (expense)012(1)(1)(1)(2)
Investment income, nonoperating  000 
Other nonoperating expense(0)(2)    
Interest and debt expense(1)(1)(2)(2) (0)
Net loss:(40)(29)(58)(51)(42)(36)
Other undisclosed net income attributable to parent1122 0
Net loss attributable to parent:(39)(28)(57)(50)(42)(35)
Other undisclosed net loss available to common stockholders, basic     (0)
Net loss available to common stockholders, diluted:(39)(28)(57)(50)(42)(35)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(40)(29)(58)(51)(42)(36)
Comprehensive loss:(40)(29)(58)(51)(42)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1122(0)0
Comprehensive loss, net of tax, attributable to parent:(39)(28)(57)(50)(42)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: